ABUS vs CAH · P/E 5.4, rev $6.2M vs P/E 35, rev $222.58B
Arbutus Biopharma Corp (ABUS) versus Cardinal Health Inc (CAH) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CAH revenue for 2025-06-30 was $222.58B. Net income was $1.57B. Revenue was down 1.9% from 2024-06-30 to 2025-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
Not investment advice. Open the ABUS and CAH stock pages for the full models.
Not investment advice.